Coya Therapeutics, Inc. Announces Positive Results from a Proof-of-Concept Academic Clinical Study for COYA 302 in Amyotrophic Lateral Sclerosis (ALS)
Following the administration of COYA 302 for 48 weeks, patients were evaluated over an 8-week washout period.
- Following the administration of COYA 302 for 48 weeks, patients were evaluated over an 8-week washout period.
- During the 48-week treatment period, COYA 302 appeared to be well tolerated.
- Preliminary efficacy of COYA 302 was measured by the ALSFRS-R scale, a validated rating tool for monitoring the progression of disability in patients with ALS.
- “We plan to file an IND with the FDA in the second half of 2023 and initiate a clinical study soon thereafter,” Dr. Hepner added.